Core Insights - Palvella Therapeutics has appointed Dr. David W. Osborne as Chief Innovation Officer to lead the expansion of its QTORIN™ platform, with a second product candidate expected to be announced by the end of 2025 [1][5] Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases that lack FDA-approved treatments [6] - The company is advancing a pipeline of product candidates based on its proprietary QTORIN™ platform, which aims to address significant unmet medical needs in dermatology [6] Leadership and Expertise - Dr. Osborne brings over 25 years of experience in drug development, having previously co-founded Arcutis Biotherapeutics and contributed to the development of multiple FDA-approved therapies [3][4] - His expertise includes formulation science and translational innovation, which will be crucial for maximizing the potential of the QTORIN™ platform [2][3] QTORIN™ Platform - The QTORIN™ platform is designed to generate novel, targeted topical therapies for rare genetic skin diseases, with a focus on overcoming technical challenges in drug formulation [2][3] - The lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is currently undergoing clinical trials for conditions such as microcystic lymphatic malformations and cutaneous venous malformations [7]

Core Insights - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases without FDA-approved treatments [1][3] - The company will present at two upcoming healthcare investor conferences, highlighting its commitment to engaging with investors [1][2] Company Overview - Founded by veterans in rare disease drug development, Palvella is dedicated to creating novel therapies for patients with serious, rare genetic skin diseases [3] - The company is developing a pipeline of product candidates using its patented QTORIN™ platform, with a focus on lifelong genetic skin diseases [3] - Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is currently in Phase 3 and Phase 2 clinical trials for specific conditions [3] Upcoming Events - Wes Kaupinen, the CEO, will present at the Cantor Global Healthcare Conference on September 4, 2025, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [2] - Live webcasts of the presentations will be available on Palvella's website, with archived replays accessible for approximately 90 days [2]